This is a working overview of reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-24 and is reviewed periodically as new material appears.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
| Property | Value | Notes |
|---|---|---|
| Storage of dry powder | -20 °C or below | Common practice for long-term retention |
| Storage after reconstitution | 2-8 °C, short term | Solution stability is limited compared with dry powder |
| Typical analytical method | Reversed-phase HPLC | Usually paired with mass spectrometry for mass confirmation |
| Detection wavelength | About 214 nm | Peptide backbone absorbance; buffer background must be controlled |
| Counter-ion forms | Acetate or trifluoroacetate | Affects mass balance and reported concentration |
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
=== Major depressive disorder === The mechanistic rationale for KOR antagonism in major depressive disorder (MDD) derives from the observation that chronic stress and depression are associated with higher activity of the KOR system. KOR activation suppresses dopamine release and prevents dopamine rebound after stress exposure, thereby leading to anhedonia and depressive phenotypes. KOR antagonists reverse this pathway by disinhibiting dopaminergic tone and restoring reward sensitivity. KOR-mediated upregulation of pro-inflammatory signaling in microglia likely drives the depression pathophysiology, and antagonism may provide benefits. The claustrum-prelimbic cortex circuit operates via dynorphin and KOR signaling to modulate cognitive and affective functions. Buprenorphine/samidorphan (ALKS-5461) displayed antidepressant efficacy in randomized controlled trials as an adjunctive therapy and has shown durable effects with a favorable safety profile including low abuse potential and minimal withdrawal symptoms. A phase 2 study demonstrated significant reduction of depressive symptoms and improvement in anhedonia when aticaprant was added to existing antidepressant therapy. A phase 3 clinical trials (KOASTAL-1 and additional studies) of navacaprant failed to achieve statistically significant superiority over placebo across the broader MDD population, with its development discontinued for this purpose in early 2025.
== Therapeutic potential == Like other opioids, it has potential in pain management; however, by being selective for the delta receptor, multiple undesirable side effects of traditional opioids are not present, such as respiratory depression, sedation, and euphoria. ADL-5859 was also found to be orally active, which makes it easier to administer. Multiple tests have shown its efficacy as an analgesic. It also did not seem to be a convulsant, unlike some other delta agonist opioids.
The Montessori Middle School Program completes the Montessori studies for students progressing to the seventh and eighth grades. An interdisciplinary teaching team provides the Montessori Program for multidisciplinary learning to include English Language Arts, mathematics, science and social studies. At the high school level, the student can apply for entry to Biotechnology, Biomedical, Military Academy, Center for the Visual & Performing Arts and/or the Science & Technology Center. Locations:
In 1998, after 38 years of ownership, Monaghan announced his retirement, sold 93 percent of the company to Bain Capital, Inc. for about $1 billion, and ceased being involved in day-to-day operations of the company. A year later, the company named Dave Brandon as its CEO.
Sources: en.wikipedia.org
== Medical uses == Lurasidone is used to treat schizophrenia and bipolar disorder. In bipolar disorder, it has been studied both as a monotherapy and adjunctive treatment to lithium or valproate. The European Medicines Agency approved lurasidone for the treatment of schizophrenia for people aged 13 years and older. Its use in Europe for bipolar disorder is considered off-label. In the United States, it is used to treat schizophrenia for people aged 13 years and older. In July 2013, lurasidone received approval for bipolar I depression. This includes depressive episodes of bipolar disorder age 10 and over as a monotherapy, and in conjunction with lithium or valproate in adults. In June 2020, lurasidone was approved in Japan, eight years after its first approval in the United States. In Japan it is approved for bipolar depression and schizophrenia. Lurasidone is not approved by the Food and Drug Administration (FDA) for the treatment of behavior disorders in older adults with dementia. Few available atypical antipsychotics are known to possess antidepressant efficacy in bipolar disorder (with the notable exceptions being cariprazine, quetiapine, olanzapine and possibly asenapine) as a monotherapy. The majority of atypical antipsychotics are known to possess significant antimanic activity, however lurasidone is unusual as it was never studied for acute mania.
=== Energy source === Anabolism is powered by catabolism, where large molecules are broken down into smaller parts and then used up in cellular respiration. Many anabolic processes are powered by the cleavage of adenosine triphosphate (ATP). Anabolism usually involves reduction and decreases entropy, making it unfavorable without energy input. The starting materials, called the precursor molecules, are joined using the chemical energy made available from hydrolyzing ATP, reducing the cofactors NAD+, NADP+, and FAD, or performing other favorable side reactions. Occasionally it can also be driven by entropy without energy input, in cases like the formation of the phospholipid bilayer of a cell, where hydrophobic interactions aggregate the molecules.
The third generation of the Familia Presto was announced in September 1973, a month before the 1973 oil crisis. It was basically an updated version of the 1970 Familia Presto, reintroduced with 60 mm wider bodywork and reworked front and rear designs. It was promoted and marketed as the "Widebody" in Japan. These changes were made only to the saloons and coupé, while the van/wagon and pickups remained in production and retaining the original narrower bodywork with minor changes. The Familia Presto continued using the "Mazda 1000/1300" name in most export markets, "Mazda Marella" name was also retained in Finland. The Rotary Presto saloon/coupé was discontinued in Japan, having been replaced by the larger Grand Familia-based Mazda Savannah. The piston-engined 1000/1300 and rotary-engined R100 coupés were also replaced by 808/818/RX-3 coupé for export market. This generation was not available in North America and replaced by the bigger 808/Mizer/RX-3. Developed to meet new stricter emissions standards in the domestic market, the Presto featured the 1272 cc TC engine or the by now familiar, pushrod 1.0-litre PB unit. Power outputs in Japan (JIS gross) are 62 PS (46 kW; 61 hp) and 87 PS (64 kW; 86 hp) respectively, 50 PS (37 kW; 49 hp) and 66 PS (49 kW; 65 hp) (DIN) for export markets. Production of the third generation Familia ended in January 1977, but not before another minor facelift and emissions scrubbing had taken place in February 1976. This changes were not applied for export market.
Sources: en.wikipedia.org
Produced by Robert Eagle, directed by Patrick Fleming, made by Eagle & Eagle, with The Learning Channel. Shown on TLC in 1999 20 September Do Parents Matter?, about the psychological needs of children; the psychiatrist Stanley Greenspan; the book The Nurture Assumption by Judith Rich Harris argued that a child's associates shaped their personality, as seen most commonly in their teenage years; teenage subdivisions in the USA - the 'populars' and the 'jocks'; at university, Judith Harris had her study stopped by the famous psychology academic George Armitage Miller; Thomas J. Bouchard Jr. at the University of Minnesota and his study of separated identical twins and the effect of genes, which he estimated to be around 50%; the effect of the home was thought to account for the other 50%, but psychologists did not find anything like that; work by psychologist Carolyn Rovee-Collier; primatology and work by Frans de Waal; childhood studies by William Corsaro influenced findings; the 'normals' teenage subdivision; the 1953 Asch conformity experiments on teenagers by psychologist Solomon Asch, with five stooges in a group of six teenagers that would often exert group influence over the sixth teenager, helped findings; a similar effect was deployed in the Candid Camera series, to convince people; the 'skaters' teenage subdivision; further studies on conformity in the Stanford prison experiment of 1971 by Philip Zimbardo - the BBC made the 2002 documentary The Experiment; the 'loners' teenage subdivision.
== Efficacy and side effects == Counterintuitively to the drastic effect of thinly winged insect-venom on neurological processes, some toxins of these hymenopteran insects are used in the field of medicine. An example can be found in tertiapin-Q from the European honey bee (Apis mellifera) which is used in the treatment of pain, multiple sclerosis (MS), and rheumatoid arthritis. The spider wasp is also a hymenopteran insect but its pompilidotoxins are currently not linked to any existing drugs. Therefore there are also no indications for these compounds. PMTXs medical potential has been considered in the past but to no avail. Their possible characteristic to only enhance neuronal activity has already been nullified as early as in 1998 by Harsch et.al who experimentally found that α-PMTX could also disrupt the activity of rat cortical neurons irreversibly and immediately upon administration. The unpredictability of the toxin and the still rather large gap in information on the toxin, contribute to it not having been translated into medicine. However, even though pompilidotoxins are not used as drugs, they do hold a large medical value. This value comes forth from the fact that this neurotoxin of 13 amino acids is so much smaller than its fellow sodium channel-specific polypeptide toxins. For example, pompilidotoxins are much smaller than the conventionally studied sea anemone toxin that has 46 to 49 amino acids, or the α-scorpion toxin of even 60 to 65 residues.
Pheochromocytoma Prolactin-dependent tumors such as pituitary prolactinomas and breast cancer Long QT syndrome Coma Circulatory collapse Subcortical brain damage Blood dyscrasia Parkinson's disease Dementia with Lewy bodies
=== Patent litigation === In May 2009, Johnson & Johnson's Centocor unit, the maker of infliximab, won a ruling for $1.67 billion from Abbott Laboratories for patent infringement on the process for making Humira. However, in 2011, the judgment was overturned by the United States Court of Appeals for the Federal Circuit. In June 2020, a class action lawsuit filed by United Food and Commercial Workers Local 1500 (UFCW Local 1500) against AbbVie, alleging that the drug manufacturer used a patent thicket over 100 strong to maintain a monopoly on Adalimumab, was dismissed by the Northern District Court in Illinois. The dismissal was affirmed by the Seventh Circuit Court of Appeals on 1 August 2022. AbbVie has extensively used the US patent system to delay competitors from entering the market, a process commonly known as "evergreening". It filed 311 patents for Humira, of which 165 were granted. AbbVie sued Amgen, the manufacturer of Amjevita, in 2016 for violating 10 of its patents. Amgen agreed to delay sales until 2023, which allowed AbbVie to drive up prices of Humira. Between 2016 and 2023, the price of Humira went up by 60%, during which time AbbVie made $114 billion in revenue from Humira.
Sources: en.wikipedia.org
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.
Reconstituted solutions are typically kept refrigerated at two to eight degrees Celsius when used within a short window, or frozen in aliquots for longer periods. Repeated freeze-thaw cycles are avoided because they can reduce recovery of intact peptide.
It establishes that the measured mass matches the expected value for the intact molecule. It also helps detect modifications such as oxidation or truncation that shift the mass by a known amount.
Cycling between frozen and liquid states can promote aggregation and adsorption to container walls. Dividing a stock into single-use aliquots limits the number of cycles a given vial undergoes.